The imaging substudy is an afterthought in the protocol and the centrepiece of the debate
The trials measured mass. Nobody measured whether the participants got weaker.
Archive — April 2026
Page 2 of 5 of this archive, newest first.
The supply gap as a clinical event
Cost is the modal reason for discontinuation in every dataset we have seen, and it is absent from the clinical literature.
What changed at QST in April, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
PeptideMeter result on a Changsha mazdutide lot lands 1.3 points below the supplier’s figure
A reminder that a purity figure is the output of a method, and that methods differ.
Inspectors cite the relabeller trading as Vantris Bio over sterility assurance
The observation that closes a facility is rarely the dramatic one.
What the new Argentina guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Janoshik, Medutest, PeptideMeter, VendorInvestigate: a capability audit
We asked all four services what they can determine, on what timescale, at what price, and under what accreditation. The answers are printed in full.
The 13-day notice: how a compounding wind-down works in South Africa
The document is four pages. Three of them are about dates.
Inspectors cite Calder Vale Peptides of Skipton over sterility assurance
The observation that closes a facility is rarely the dramatic one.
Ireland declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
WXT declines, for the 8th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Two documents, two disciplines: purity and sterility are not the same trade
The Journal has read several hundred certificates from twenty companies. We set out what the documents actually cover, and what a reader is filling in from imagination.
Janoshik, Medutest, PeptideMeter, VendorInvestigate: a capability audit
The absence of microbiological capability in this market is a commercial fact with a straightforward explanation, and it is worth understanding before blaming anybody for it.
EGFR, cystatin C, and the check on the check
What the renal and hepatic outcome programmes actually measured, and over what duration.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
PeptideMeter result on a Hangzhou orforglipron lot lands 0.7 points below the supplier’s figure
The result is unremarkable. What the report omits is not.
What changed at Homopeptide in April, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
How a release document is put together in a regulated plant
Nothing on this page is difficult. It is simply unfamiliar, and unfamiliarity is what makes a weak certificate look like a strong one.
What the trials counted as intolerance
The ceiling varies severalfold between people, and nothing measurable at baseline predicts where it sits.
What the new Japan guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Independent analysis puts a SWB liraglutide lot at 95.6%, against 93.9% on the certificate
The report states the gradient, the wavelength and the integration threshold, which is more than most.
Hangzhou export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
A shortage listing ends. 17 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
What a diode array adds, and why the certificate never shows it
Non-chromophoric components — counter-ions, salts, some excipients — contribute mass to the vial and nothing at all to the chromatogram.
A shortage listing ends. 8 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
STEP 1 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Brazil health authority warns on falsified dulaglutide pens
Reported from the analysis, not from a warning notice.
Inspectors cite the relabeller trading as Vantris Bio over sterility assurance
The observation that closes a facility is rarely the dramatic one.
Target dose, effective dose, and the distance between them
What the trials measured was continuation against withdrawal. What patients want to know is continuation at a lower dose, and that study has largely not been done.
Aseptic technique for people who were never taught it
A needle blunts on first use. Reuse is uncomfortable, and it is a documented contributor to lipohypertrophy.
The named comparison we promised two years ago
The Journal submitted split samples from single lots to three assay services, under names unconnected to this publication, and published each method alongside each result.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
What changed at SGN in April, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
South Africa caps exenatide prescribing to 20 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
What a low result means when intake has halved
Reduced intake is a plausible mechanism for deficiency. Reduced absorption is not, and the two are conflated in most of the advice.
Deamidation is the commonest degradation route and the hardest to see
An isoaspartate rearrangement changes the molecule and not the mass. A method that confirms identity by molecular weight alone will report it as the parent compound.
SURMOUNT-4 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A shortage listing ends. 13 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
Halvard & Pike Apothecary of Portland, Maine enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.